Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025506 · ClinicalTrials.gov registry record · Phase 2
Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT00025506: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00025506 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00025506, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
This phase II trial is studying how well thalidomide works in treating patients with carcinosarcoma of the uterus that has come back or that does not go to remission (decrease or disappear but may still be in the body) despite treatment. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2001-09 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00025506
The ClinicalTrials.gov registry entry for NCT00025506 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00025506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00025506 about?
NCT00025506 is a clinical study titled "Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus". This phase II trial is studying how well thalidomide works in treating patients with carcinosarcoma of the uterus that has come back or that does not go to remission (decrease or disappear but may still be in the body) despite treatment. Thalidomide may stop the growth of cancer by stopping blood fl...
What is the current status of trial NCT00025506?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2001-09. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00025506?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00025506?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.